Materials technology in drug eluting balloons: Current and future perspectives

Journal of Controlled Release

Volumn 239, Issue , 2016, Pages 92-106

  Xiong, Gordon Minru ^a   Ang, Huiying ^b   Lin, Jinjie ^b   Lui, Yuan Siang ^a   Phua, Jie Liang ^a   Chan, Jing Ni ^a   Venkatraman, Subbu ^a   Foin, Nicolas ^b   Huang, Yingying ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

Coating excipient; Drug eluting balloon; Nanoliposome; Particulate generation; Polymeric nanocarrier

Indexed keywords

BALLOONS; HISTOLOGY; MEDICAL APPLICATIONS; NANOTECHNOLOGY; PLATING; STENTS; TISSUE;

BIOMEDICAL APPLICATIONS; COATING TECHNOLOGIES; FUTURE PERSPECTIVES; INTERVENTIONAL CARDIOLOGY; MATERIALS TECHNOLOGY; NANOCARRIERS; NANOLIPOSOME; PARTICULATE GENERATION;

COATINGS;

BUTYRYL TRI HEXYL CITRATE; DEXTRAN; EXCIPIENT; IOPROMIDE; MACROGOL; POLYSORBATE; SHELLAC; SORBITOL; UNCLASSIFIED DRUG; UREA; NANOMATERIAL; PACLITAXEL;

ANTIPROLIFERATIVE ACTIVITY; ARTERIAL TISSUE; BALLOON; CARDIAC PATIENT; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELUTING BALLOON; DRUG ELUTING STENT; DRUG RETENTION; DRUG STORAGE; DRUG UPTAKE; HUMAN; HYDROGEL; IN-STENT RESTENOSIS; MATERIAL COATING; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); MATERIALS TESTING; METABOLISM; PROCEDURES; PROSTHESIS DESIGN; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; MATERIALS TESTING; NANOSTRUCTURES; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; PROSTHESIS DESIGN;

EID: 84984853485     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.08.018     Document Type: Review

References (70)

1. [1] Kempin, W., Kaule, S., Reske, T., Grabow, N., Petersen, S., Nagel, S., Schmitz, K.P., Weitschies, W., Seidlitz, A., In vitro evaluation of paclitaxel coatings for delivery via drug-coated balloons. Eur. J. Pharm. Biopharm. 96 (2015), 322–328.
2. [2] Kirtane, A.J., Gupta, A., Iyengar, S., Moses, J.W., Leon, M.B., Applegate, R., Brodie, B., Hannan, E., Harjai, K., Jensen, L.O., Park, S.J., Perry, R., Racz, M., Saia, F., Tu, J.V., Waksman, R., Lansky, A.J., Mehran, R., Stone, G.W., Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 119 (2009), 3198–3206.
3. [3] Huang, Y., Ng, H.C., Ng, X.W., Subbu, V., Drug-eluting biostable and erodible stents. J. Control. Release 193 (2014), 188–201.
4. [4] Joner, M., Finn, A.V., Farb, A., Mont, E.K., Kolodgie, F.D., Ladich, E., Kutys, R., Skorija, K., Gold, H.K., Virmani, R., Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48 (2006), 193–202.
5. [5] Waksman, R., Pakala, R., Drug-eluting balloon: the comeback kid?. Circ. Cardiovasc. Interv. 2 (2009), 352–358.
6. [6] Sgueglia, G.A., Foin, N., Todaro, D., Stipo, A., Davies, J.E., Gaspardone, A., Di Mario, C., Pucci, E., First optical coherence tomography follow-up of coronary bifurcation lesions treated by drug-eluting balloons. J. Invasive Cardiol. 27 (2015), 191–198.
7. [7] Byrne, R.A., Joner, M., Alfonso, F., Kastrati, A., Drug-coated balloon therapy in coronary and peripheral artery disease. Nat. Rev. Cardiol. 11 (2014), 13–23.
8. [8] Unverdorben, M., Vallbracht, C., Cremers, B., Heuer, H., Hengstenberg, C., Maikowski, C., Werner, G.S., Antoni, D., Kleber, F.X., Bocksch, W., Leschke, M., Ackermann, H., Boxberger, M., Speck, U., Degenhardt, R., Scheller, B., Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119 (2009), 2986–2994.
9. [9] Rittger, H., Brachmann, J., Sinha, A.M., Waliszewski, M., Ohlow, M., Brugger, A., Thiele, H., Birkemeyer, R., Kurowski, V., Breithardt, O.A., Schmidt, M., Zimmermann, S., Lonke, S., von Cranach, M., Nguyen, T.V., Daniel, W.G., Wohrle, J., A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J. Am. Coll. Cardiol. 59 (2012), 1377–1382.
10. [10] Cassese, S., Byrne, R.A., Ott, I., Ndrepepa, G., Nerad, M., Kastrati, A., Fusaro, M., Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ. Cardiovasc. Interv. 5 (2012), 582–589.
11. [11] Laird, J.R., Armstrong, E.J., J. Am. Coll. Cardiol. 64 (2014), 1577–1579.
12. [12] Katsanos, K., Karnabatidis, D., Kitrou, P., Spiliopoulos, S., Christeas, N., Siablis, D., Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial. J. Endovasc. Ther. 19 (2012), 263–272.
13. [13] Kitrou, P.M., Katsanos, K., Spiliopoulos, S., Karnabatidis, D., Siablis, D., Drug-eluting versus plain balloon angioplasty for the treatment of failing dialysis access: final results and cost-effectiveness analysis from a prospective randomized controlled trial (NCT01174472). Eur. J. Radiol. 84 (2015), 418–423.
14. [14] Spiliopoulos, S., Endovascular today - drug-coated balloons: what's their role in AV access?. Endovasc. Today, 2015.
15. [15] Bandomir, J., Kaule, S., Schmitz, K.-P., Sternberg, K., Petersen, S., Kragl, U., Usage of different vessel models in a flow-through cell: in vitro study of a novel coated balloon catheter. RSC Adv. 5 (2015), 11604–11610.
16. [16] Burke, S.E., Kuntz, R.E., Schwartz, L.B., Zotarolimus (ABT-578) eluting stents. Adv. Drug Deliv. Rev. 58 (2006), 437–446.
17. [17] Creel, C.J., Lovich, M.A., Edelman, E.R., Arterial paclitaxel distribution and deposition. Circ. Res. 86 (2000), 879–884.
18. [18] Levin, A.D., Vukmirovic, N., Hwang, C.-W., Edelman, E.R., Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. PNAS 101 (2004), 9463–9467.
19. [19] Granada, J.F., Milewski, K., Zhao, H., Stankus, J.J., Tellez, A., Aboodi, M.S., Kaluza, G.L., Krueger, C.G., Virmani, R., Schwartz, L.B., Nikanorov, A., Vascular response to zotarolimus-coated balloons in injured superficial femoral arteries of the familial hypercholesterolemic swine. Circ. Cardiovasc. Interv. 4 (2011), 447–455.
20. [20] Kolachalama, V.B., Pacetti, S.D., Franses, J.W., Stankus, J.J., Zhao, H.Q., Shazly, T., Nikanorov, A., Schwartz, L.B., Tzafriri, A.R., Edelman, E.R., Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy. Circulation 127 (2013), 2047–2055.
21. [21] Tzafriri, A.R., Vukmirovic, N., Kolachalama, V.B., Astafieva, I., Edelman, E.R., Lesion complexity determines arterial drug distribution after local drug delivery. J. Control. Release 142 (2010), 332–338.
22. [22] Gongora, C.A., Shibuya, M., Wessler, J.D., McGregor, J., Tellez, A., Cheng, Y., Conditt, G.B., Kaluza, G.L., Granada, J.F., Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral In-stent restenosis. JACC Cardiovasc. Interv. 8 (2015), 1115–1123.
23. [23] Sarode, K., Spelber, D.A., Bhatt, D.L., Mohammad, A., Prasad, A., Brilakis, E.S., Banerjee, S., Drug delivering technology for endovascular management of infrainguinal peripheral artery disease. JACC Cardiovasc. Interv. 7 (2014), 827–839.
24. [24] Seidlitz, A., Kotzan, N., Nagel, S., Reske, T., Grabow, N., Harder, C., Petersen, S., Sternberg, K., Weitschies, W., In vitro determination of drug transfer from drug-coated balloons. PLoS One, 8, 2013, e83992.
25. [25] Granada, J.F., Stenoien, M., Buszman, P.P., Tellez, A., Langanki, D., Kaluza, G.L., Leon, M.B., Gray, W., Jaff, M.R., Schwartz, R.S., Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart, 1, 2014.
26. [26] Deng, J., Huang, L., Liu, F., Understanding the structure and stability of paclitaxel nanocrystals. Int. J. Pharm. 390 (2010), 242–249.
27. [27] Carlyle, W.C., McClain, J.B., Tzafriri, A.R., Bailey, L., Zani, B.G., Markham, P.M., Stanley, J.R.L., Edelman, E.R., Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. J. Control. Release 162 (2012), 561–567.
28. [28] Farah, S., Khan, W., Domb, A.J., Crystalline coating of rapamycin onto a stent: process development and characterization. Int. J. Pharm. 445 (2013), 20–28.
29. [29] Scheller, B., Speck, U., Abramjuk, C., Bernhardt, U., Bohm, M., Nickenig, G., Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110 (2004), 810–814.
30. [30] Buszman, P.P., Tellez, A., Afari, M.E., Peppas, A., Conditt, G.B., Rousselle, S.D., McGregor, J.C., Stenoien, M., Kaluza, G.L., Granada, J.F., Tissue uptake, distribution, and healing response after delivery of paclitaxel via second-generation iopromide-based balloon coating: a comparison with the first-generation technology in the iliofemoral porcine model. JACC Cardiovasc. Interv. 6 (2013), 883–890.
31. [31] Wohrle, J., Zadura, M., Mobius-Winkler, S., Leschke, M., Opitz, C., Ahmed, W., Barragan, P., Simon, J.P., Cassel, G., Scheller, B., SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J. Am. Coll. Cardiol. 60 (2012), 1733–1738.
32. [32] Werk, M., Albrecht, T., Meyer, D.R., Ahmed, M.N., Behne, A., Dietz, U., Eschenbach, G., Hartmann, H., Lange, C., Schnorr, B., Stiepani, H., Zoccai, G.B., Hanninen, E.L., Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ. Cardiovasc. Interv. 5 (2012), 831–840.
33. [33] Lamichhane, S., Anderson, J., Remund, T., Kelly, P., Mani, G., Dextran sulfate as a drug delivery platform for drug-coated balloons: preparation, characterization, in vitro drug elution, and smooth muscle cell response. J. Biomed. Mater. Res. B Appl. Biomater., 2015.
34. [34] Anderson, J.A., Lamichhane, S., Remund, T., Kelly, P., Mani, G., Preparation, characterization, in vitro drug release, and cellular interactions of tailored paclitaxel releasing polyethylene oxide films for drug-coated balloons. Acta Biomater. 29 (2016), 333–351.
35. [35] Stella, P.R., Belkacemi, A., Agostoni, P., Drug-eluting balloons and bifurcations, a new future?. EuroIntervention 6 (2011), J161–J164.
36. [36] Yazdani, S.K., Pacheco, E., Nakano, M., Otsuka, F., Naisbitt, S., Kolodgie, F.D., Ladich, E., Rousselle, S., Virmani, R., Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter. Cardiovasc. Interv. 83 (2014), 132–140.
37. [37] Matsumoto, A.H., Barth, K.H., Selby, J.B. Jr., Tegtmeyer, C.J., Peripheral angioplasty balloon technology. Cardiovasc. Intervent. Radiol. 16 (1993), 135–143.
38. [38] Warner, J.A., Forsyth, B., Zhou, F., Myers, J., Frethem, C., Haugstad, G., Characterization of Pebax angioplasty balloon surfaces with AFM, SEM, TEM, and SAXS. J. Biomed. Mater. Res. B Appl. Biomater. 104 (2016), 470–475.
39. [39] Djebbar, M.K., Nguyen, Q.T., Clement, R., Germain, Y., Pervaporation of aqueous ester solutions through hydrophobic poly(ether-block-amide) copolymer membranes. J. Membr. Sci. 146 (1998), 125–133.
40. [40] Tretinnikov, O.N., Ikada, Y., Dynamic wetting and contact-angle hysteresis of polymer surfaces studies with the modified Wilhelmy balance method. Langmuir 10 (1994), 1606–1614.
41. [41] Subbu, V., Kevin, K., Yitzhak, R., Yingying, H., Terry, W.J.S., Frank, A., Drug Delivery Systems for Vascular Disease Therapy. Polymers for Vascular and Urogenital Applications, 2012, CRC Press, 5–38.
42. [42] Gray, W.A., Granada, J.F., Drug-coated balloons for the prevention of vascular restenosis. Circulation 121 (2010), 2672–2680.
43. [43] Schnorr, B., Kelsch, B., Cremers, B., Clever, Y.P., Speck, U., Scheller, B., Paclitaxel-coated balloons - survey of preclinical data. Minerva Cardioangiol. 58 (2010), 567–582.
44. [44] Posa, A., Hemetsberger, R., Petnehazy, O., Petrasi, Z., Testor, M., Glogar, D., Gyongyosi, M., Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries. Coron. Artery Dis. 19 (2008), 243–247.
45. [45] Vaquerizo, B., Aizpurua, D.A., Cuscullida, J.C., Penaranda, A.S., Update on drug-eluting balloons for percutaneous coronary interventions. EMJ Int. Cardiol. 1 (2013), 80–90.
46. [46] Kirsten Peters, C.P., Salamon, A., Rychly, J., Neumann, H.-G., In vitro evaluation of cytocompatibility of shellac as coating for intravascular devices. Trends Biomater. Artif. Organs 26 (2012), 110–113.
47. [47] Radke, P., Joner, M., Joost, A., Byrne, R.A., Hartwig, S., Bayer, G., Steigerwald, K., Wittchow, E., Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipient. EuroIntervention 7 (2011), 730–737.
48. [48] Cheng, Y., Leon, M.B., Granada, J.F., An update on the clinical use of drug-coated balloons in percutaneous coronary interventions. Expert Opin. Drug Deliv., 2016, 1–14.
49. [49] Scheinert, D., Duda, S., Zeller, T., Krankenberg, H., Ricke, J., Bosiers, M., Tepe, G., Naisbitt, S., Rosenfield, K., The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc. Interv. 7 (2014), 10–19.
50. [50] Kaule, S., Minrath, I., Stein, F., Kragl, U., Schmidt, W., Schmitz, K.P., Sternberg, K., Petersen, S., Correlating coating characteristics with the performance of drug-coated balloons–a comparative in vitro investigation of own established hydrogel- and ionic liquid-based coating matrices. PLoS One, 10, 2015, e0116080.
51. [51] van Vlerken, L.E., Vyas, T.K., Amiji, M.M., Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 24 (2007), 1405–1414.
52. [52] Gongora, C.A., Shibuya, M., Wessler, J.D., McGregor, J., Tellez, A., Cheng, Y., Conditt, G.B., Kaluza, G.L., Granada, J.F., Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral In-stent restenosis. J. Am. Coll. Cardiol. Intv. 8 (2015), 1115–1123.
53. [53] Kelsch, B., Scheller, B., Biedermann, M., Clever, Y., Schaffner, S., Mahnkopf, D., Speck, U., Cremers, B., Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Investig. Radiol. 46 (2011), 255–263.
54. [54] Zeller, T., Baumgartner, I., Scheinert, D., Brodmann, M., Bosiers, M., Micari, A., Peeters, P., Vermassen, F., Landini, M., Snead, D.B., Kent, K.C., Rocha-Singh, K.J., Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J. Am. Coll. Cardiol. 64 (2014), 1568–1576.
55. [55] Siskin, G.P., Dowling, K., Virmani, R., Jones, R., Todd, D., Pathologic evaluation of a spherical polyvinyl alcohol embolic agent in a porcine renal model. J. Vasc. Interv. Radiol. 14 (2003), 89–98.
56. [56] Ward, C., Mena, C.I., Detection of paclitaxel contamination resulting from the simulated clinical use of drug coated balloon catheters. J. Am. Coll. Cardiol., 64, 2014, B83.
57. [57] Chan, J.M., Rhee, J.-W., Drum, C.L., Bronson, R.T., Golomb, G., Langer, R., Farokhzad, O.C., In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid–polymeric nanoparticles. PNAS 108 (2011), 19347–19352.
58. [58] Zou, W., Cao, G., Xi, Y., Zhang, N., New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv. 16 (2009), 15–23.
59. [59] Guzman, L.A., Labhasetwar, V., Song, C., Jang, Y., Lincoff, A.M., Levy, R., Topol, E.J., Local intraluminal infusion of biodegradable polymeric nanoparticles a novel approach for prolonged drug delivery after balloon angioplasty. Circulation 94 (1996), 1441–1448.
60. [60] Westedt, U., Barbu-Tudoran, L., Schaper, A.K., Kalinowski, M., Alfke, H., Kissel, T., Deposition of nanoparticles in the arterial vessel by porous balloon catheters: localization by confocal laser scanning microscopy and transmission electron microscopy. AAPS PharmSci 4 (2002), 206–211.
61. [61] Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65 (2013), 36–48.
62. [62] Lemos, P.A., Farooq, V., Takimura, C.K., Gutierrez, P.S., Virmani, R., Kolodgie, F., Christians, U., Kharlamov, A., Doshi, M., Sojitra, P., van Beusekom, H.M., Serruys, P.W., Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention 9 (2013), 148–156.
63. [63] Haeri, A., Sadeghian, S., Rabbani, S., Anvari, M.S., Lavasanifar, A., Amini, M., Dadashzadeh, S., Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes. Int. J. Pharm. 455 (2013), 320–330.
64. [64] Yin, Y., Wu, X., Yang, Z., Zhao, J., Wang, X., Zhang, Q., Yuan, M., Xie, L., Liu, H., He, Q., The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension. Pharm. Res. 30 (2013), 2050–2062.
65. [65] Lee, M.-K., Lim, S.-J., Kim, C.-K., Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28 (2007), 2137–2146.
66. [66] Yu, Q., Hu, X., Ma, Y., Xie, Y., Lu, Y., Qi, J., Xiang, L., Li, F., Wu, W., Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv. 0 (2016), 1–7.
67. [67] Gasper, W.J., Jimenez, C.A., Walker, J., Conte, M.S., Seward, K., Owens, C.D., Adventitial nab-rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial inflammation. Circ. Cardiovasc. Interv. 6 (2013), 701–709.
68. [68] Fu, Q., Sun, J., Zhang, W., Sui, X., Yan, Z., He, Z., Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat. Anticancer Drug Discov. 4 (2009), 262–272.
69. [69] Margolis, J., McDonald, J., Heuser, R., Klinke, P., Waksman, R., Virmani, R., Desai, N., Hilton, D., Systemic nanoparticle paclitaxel (nab-paclitaxel) for In-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study. Clin. Cardiol. 30 (2007), 165–170.
70. [70] Camici, G.G., Steffel, J., Amanovic, I., Breitenstein, A., Baldinger, J., Keller, S., Lüscher, T.F., Tanner, F.C., Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur. Heart J. 31 (2010), 236–242.